Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881879 | 1.00 | HPGD (0.38) | HPGDGAASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL1888659 | 0.91 | HPGD (0.38) | HPGDGAASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL1886213 | 0.91 | HPGD (0.38) | HPGDGAASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL19065277 | 0.82 | GABBR2 (0.43) | HPGDGAASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1881880 | 0.80 | SMN1; SMN2 (0.41) | HPGDGAASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL27693069 | 0.79 | GAA (0.52) | HPGDGAASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL1885017 | 0.78 | MAPT (0.40) | HPGDSMN1; SMN2L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1884874 | 0.78 | MAPT (0.40) | HPGDSMN1; SMN2L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1886547 | 0.78 | ADRB2 (0.43) | SMN1; SMN2L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL1893283 | 0.78 | ADRB2 (0.43) | SMN1; SMN2L3MBTL1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7494985-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111325-A1 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | APEH, AASDHPPT, AGPS | HPGD 1458/4885GAA 553/4885SMN1; SMN2 900/4885 |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | HPGD 1458/4885GAA 553/4885SMN1; SMN2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.